Business description: Avacta Group Plc

Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.

Number of employees: 151

Sales by Activity: Avacta Group Plc

Fiscal Period: December 2020 (GBP) 2021 (GBP) 2022 (GBP) 2023 (GBP) 2024 (GBP)

Therapeutics

1.62M 2.16M 5.48M 2.06M 113K

Diagnostics

519K 779K 4.17M 21.19M -

Animal Health

1.49M - - - -

Geographical breakdown of sales: Avacta Group Plc

Fiscal Period: December 2020 (GBP) 2021 (GBP) 2022 (GBP) 2023 (GBP) 2024 (GBP)

South Korea

- 1.4M 5.48M 2.06M 113K

Rest of World

- - - 613K -

France

- - 1.3M 4.12M -

Rest of Asia

- 74K 7K - -

Rest of Europe

685K 111K 158K 3.69M -

North America

402K 815K 179K 21K -

Asia

1.47M - - - -

United Kingdom

1.08M 540K 2.53M 12.75M -

Executive Committee: Avacta Group Plc

Manager TitleAgeSince
Chief Executive Officer 56 31/03/2024
Director of Finance/CFO 51 21/01/2025
Chief Tech/Sci/R&D Officer - 08/02/2026
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer - 30/06/2025

Composition of the Board of Directors: Avacta Group Plc

Director TitleAgeSince
Director/Board Member 60 02/02/2020
Director/Board Member 71 16/08/2021
Director/Board Member 56 17/03/2022
Chairman 59 23/06/2024
Director/Board Member 59 27/05/2025
Director/Board Member 58 27/05/2025

Shareholders: Avacta Group Plc

NameEquities%Valuation
Hargreaves Lansdown Fund Managers Ltd.
8.765 %
38,604,000 8.765 % 39 M p
IG Markets Ltd.
3.014 %
13,273,000 3.014 % 13 M p
Lombard Odier Asset Management (Europe) Ltd.
2.648 %
11,662,726 2.648 % 12 M p
Conifer Management LLC
2.648 %
11,662,726 2.648 % 12 M p
HSBC Global Asset Management (UK) Ltd.
1.613 %
7,104,000 1.613 % 7 M p

Company details: Avacta Group Plc

Avacta Group Plc

Scale Space

W12 7RZ, London

+44 203 9110353

http://www.avacta.com
address Avacta Group Plc(AVCT)

Bio Therapeutic Drugs

Change 5d. change 1-year change 3-years change Capi.($)
-2.36%+7.28%+151.88%-23.44% 531M
+1.02%+3.43%+45.44%+87.52% 50.39B
-5.43%-7.43%+68.79%+55.56% 46.03B
-2.01%+10.11%+76.22%+517.30% 25.06B
-0.26%-1.11%-0.10%-12.59% 23.26B
+2.21%+2.33%+40.13%-27.74% 17.24B
-1.66%-4.24%+29.99%-41.30% 16.15B
-3.47%-10.60%+47.36%+185.24% 14.56B
-3.46%+5.77%-20.26%+954.65% 14.08B
-0.41%-2.86%+40.22% - 12.94B
Average -1.51%+0.05%+47.97%+188.35% 22.03B
Weighted average by Cap. -1.54%+0.02%+43.34%+166.99%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.8690GBP
Average target price
0.7925GBP
Spread / Average Target
-8.80%

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. AVCT Stock
  4. Company Avacta Group Plc